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RWJ Foundation awards $8.7-niillion grant 
for SPH substance abuse program 
Boston University School of Public Health has received the larg-
est single grant ever awarded by the Robert Wood Johnson Foun-
dation in the area of substance abuse. The $8.7-million, 
four-year grant is to be used to promote a national program to 
aid communities fighting dmg and alcohol abuse. 
The program, called Join Together, was created in 1991 to 
learn about—and ultimately to assist—community organizations 
active in the fight against substance abuse. With the RWJ Foun-
dation grant. Join Together will provide a national resource for 
community groups by helping them to identify the substance 
abuse problems in their areas, determining what strategies will 
be most effective, getting community leaders to participate in 
these coalitions and evaluating their effectiveness. 
Join Together's first effort was to conduct an extensive sur-
vey of anti-alcohol and anti-dmg groups in more than 2,000 com-
munities across the country. The results revealed that much of 
the war on dmgs is being fought at the community level, in coali-
tions that bring together individuals, businesses, religious 
groups, schools, police, government agencies and social organi-
zations. 
"We believe that communities need to organize all of their 
key leadership and institutions into a single strategy against sub-
stance abuse that covers prevention, treatment, law enforcement 
and jobs in order to be more successful," said David L. 
Rosenbloom, Ph.D., director of Join Together and an associate 
professor at the School of Public Health. 
Over the past year, Rosenbloom said. Join Together has se-
lected and trained a cadre of 30 leaders from 24 states in its Na-
tional Fellows Program, and plans to include 120 more between 
now and 1996, when the program is scheduled to end. It also 
has established two public policy panels—one to explore the 
problems communities face in preventing youth access to alco-
hol, and a second to consider substance abuse coverage as part of 
the nation's health care reform. In addition, over the next four 
years. Join Together will provide help in coaUtion-buUding and 
strategy- development to coalitions in over 800 selected cities. 
These cities can then exchange ideas through Join Together's na-
tional computer network. 
"Substance abuse, including illegal dmgs, alcohol and to-
bacco, is the most important preventable health problem plagu-
ing our nation," said Steven Schroeder, president of the 
Princeton, N.J.-based Robert Wood Johnson Foundation, the na-
tion's largest health-care philanthropy. "Join Together was cre-
ated to assist community coalitions take the lead in the fight 
against alcohol and dmgs." 
Join Together also monitors community anti-drag activity and 
the effectiveness of various ways of fighting dmg abuse, and is-
News 
& Notes 
March 1993 
Issue #159 
Stephen Tocco, secretary for economic affairs for Gov. William Weld, 
recently visited Boston University's CityLab at 809 Albany St. City-
Lab, a biotechnology learning laboratory for high school teachers and 
their students, is a joint venture between Boston University's School of 
Medicine and School of Education. CityLab is one of the many educa-
tional! training programs here that addresses the growing worfforce de-
mand in biotechnology and health care in Massachusetts. Pictured 
with Tocco are CityLab supervisor Leslie Wolfe, PhD., center, and 
Connie Phillips, director of the CityLab program, (photo by Tracy 
Russo, BUSM's Educational Media Support Services) 
sues an annual report describing how communities rate their lead-
ers. The results are made available each spring in Join To-
gether's publication. Who Is Really Fighting the War on Drugs? 
School of Medicine's new chair 
honors Sandson and Chobanian 
The School of Medicine recently recognized the years of leader-
ship and achievement contributed consecutively by Dean Emeri-
tus John I. Sandson and Dean Aram V. Chobanian by naming a 
chair in honor of Sandson and making Chobanian the first recipi-
ent. 
The John I. Sandson Distinguished Professorship of Health 
Sciences, the result of four-and-a-half years of accumulating do-
nations by former students, colleagues and friends of Sandson's, 
recognizes the major contribution he made to the School as dean 
for 14 years (1974 to 1988) and continues to make in his ongo-
ing activities here as dean emeritus. 
Sandson increased the School's annual budget five-fold, from 
$20 million a year to $1(X) million a year, and increased research 
and other sponsored-program activities to a value of $50 million 
a year in 1987. His impact extended into the structure of the 
School, as well. He oversaw the establishment of the School of 
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Public Health, the development of a flexible curriculum—as re-
flected in the establishment of the MMEDIC (modular medical 
integrated curriculum) and the Eariy Medical School Selection 
Program—and was an advocate for the Student Revolving Loan 
Fund. 
As dean emeritus, Sandson has pursued his interests in health 
care manpower, the financing of medical education and enhanc-
ing opportunities for minorities in medicine. He also is a full-
time member of the admissions committee, which, he said, has 
given him the opportunity to observe the increase in applications 
during the last few years and the diverse, well motivated appli-
cants who are applying. 
Meanwhile, Chobanian whose internationally recognized re-
search in hypertension dates back to the ground-breaking studies 
done under Robert W. Wilkins, M.D., has shifted his primary fo-
cus to leading the School since becoming dean in 1988. 
"As dean," he said, "I am very interested in getting the Medi-
cal Campus closely integrated, in bringing in new leadership, and 
in recruiting young faculty." 
While Chobanian spends most of his time as an administrator, 
he remains one of the preeminent leaders in the study of hyper-
tension today. He is the director of the National Institutes of 
Health's Hypertension Specialized Center of Research. In addi-
tion, Chobanian received the first Lifetime Achievement Award 
in Hypertension from the American Heart Association and was a 
CO- recipient of the 1990 Modem Medicine Award for Distin-
guished Service with former Surgeon General C. Everett Koop, 
M.D. 
Researchers find no evidence 
of new virus in AIDS-like illness 
In a study of four patients with idiopathic CD4 -i- T-lymphocy-
topenia (ICL), the mysterious AIDS-like illness reported at the in-
ternational conference on AIDS last summer, researchers have 
found no evidence that the syndrome is caused by a virus or by 
any other infectious agent. 
"At this point, there is no compelling evidence for an infec-
tious etiology," said the principal investigator, Robert A. 
Duncan, M.D., a fellow in infectious diseases at the School of 
Medicine and at Boston City Hospital. 
Like AIDS, ICL is characterized by a precipitous drop in the 
number of a key group of immune cells called CD4 + T-lympho-
cy tes. This depletion of CD4 cells often is accompanied by rare 
opportunistic infections, such as Pneumocystis carinii pneumo-
nia, that are considered hallmarks of AIDS, yet there is no evi-
dence of HIV infection. 
In this study, which was published in the Feb. 11 issue of The 
New England Journal of Medicine, the patients reported none of 
the risk factors traditionally associated with AIDS, and all family 
members and sexual contacts of the patients were healthy. All 
tested negative for HIV, and researchers found no evidence of 
any other retrovirus, the family of virases to which HIV belongs. 
Moreover, the course of the illness differed from patient to pa-
tient: After treatment of their initial illness, three of the four pa-
tients remained well and, in one case, a patient's CD4 count 
steadily improved over the course of a year. 
CD4 is a marker on the surface of a subgroup of T-lympho-
cytes called helper T-cells. Helper T-cells, together with sup-
pressor T- cells, coordinate the immune responses of other 
lymphocytes, monocytes, neutrophils and natural killer cells. 
Healthy individuals have CD4 counts of between 500 and 1,6(X) 
cells per cubic millimeter of blood, while patients with ICL have 
CD4 counts below 300 cells. Patients with advanced HIV infec-
tion have CD4 counts that progressively fall below 200. 
ICL was first described in a Newsweek report in early July of 
1992. Later that month, at the Intemational AIDS Conference in 
Amsterdam, researchers described more cases. These reports 
provoked widespread media attention and some concern among 
scientists that a new strain of AIDS virus might be emerging, par-
ticularly because some of the patients did have risk factors for 
HIV infection. 
Since that time, however, there has been little evidence to in-
dicate the presence of a new virus. ICL has struck a broad spec-
trum of people—approximately 100 cases have been reported 
worldwide to date—^with few common threads among them. If 
ICL were caused by a single agent and if it were a single syn-
drome, Duncan said, scientists would expect to see a pattem in 
how the disease is spread and in who contracts it. No such pat-
tem has emerged. "My suspicion is that it has multiple etiolo-
gies and multiple clinical courses, so that this is not a syndrome, 
but a collection of syndromes," said Duncan. In addition, it ap-
pears to be an old syndrome. Scientists combing the medical lit-
erature have found reports of mysterious immune defects going 
back to the 1950s. 
In the meantime, in the absence of a single, identifiable cause, 
the only treatment for patients with ICL is to direct therapy at 
the opportunistic infections that complicate the underlying immu-
nodeficiency. 
Estrogen with progesterone lowers risk of 
endometrial cancer in menopausal women 
Women who take estrogen replacement drugs to counter the 
health problems associated with menopause can significantly re-
duce their short-term risk of developing endometrial cancer if 
they also take progesterone, according to a Boston Collaborative 
Drug Surveillance Program study led by Herschel Jick, M.D., an 
associate professor of medicine. 
In a 10-year study of women between 50 and 64 years of age 
who were members of a Washington, D.C., health maintenance 
organization, researchers identified 172 cases of endometrial can-
cer. They then compared the use of hormones in those women 
with that in 1,720 women who did not have cancer. The scien-
tists found that women who used estrogen alone had a 6.5 times 
greater risk of developing endometrial cancer than women who 
used no estrogen, but that women who combined estrogen with 
progesterone did not have an increased risk of cancer. 
Because the women in this study did not use the combined 
therapy in substantial numbers until 1986, these findings apply 
to women who have used the combined therapy for five years or 
less. Researchers say that it is still unknown whether long-term 
combined use of estrogen and progesterone can result in an in-
creased risk of endometrial cancer. 
3 
JNC updates guidelines for treatment of 
hypertension, using diuretics and beta-blockers 
In a recently published report, the Joint National Committee on 
the Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC) has updated its treatment guidelines to advise the use of 
diuretics and beta-blockers over that of newer agents, such as 
ACE inhibitors, as the preferred, first-line therapy for hyperten-
sion. 
Dean Aram V. Chobanian, a JNC member, said that two im-
portant factors influenced the committee's decision. First, while 
diuretics and beta-blockers have been shown to reduce morbidity 
and mortality among patients with hypertension, the new agents 
have not been tested in long-term trials to demonstrate their effec-
tiveness. Second, treatment with diuretics and beta-blockers is 
usually much less expensive than therapy utilizing the newer 
agents. 
Chobanian said that the newer agents should be selected for 
specific patients in whom the new drugs might have particular 
benefits, such as those with known cholesterol abnormalities, 
heart disease, diabetes or kidney problems. The report under-
scored an "urgent need" for trisds to evaluate these new drags, 
which, in addition to ACE inhibitors, include calcium antagonists 
and alpha-receptor blockers. The JNC report also said that phar-
macologic treatment should begin only after lifestyle modifica-
tions, such as weight reduction, smoking cessation, exercise and 
sodium reduction, have proven insufficient to reduce a patient's 
blood pressure. 
Fetal Alcohol Education Program 
receives MetPath Foundation grant 
The School of Medicine's Fetal Alcohol Education Program re-
cently was awarded a grant from the MetPath Foundation to de-
velop a national program for pediatricians on the prevention and 
diagnosis of fetal alcohol syndrome. The program, which will in-
clude a training program and educational materials, is directed by 
Lyn Weiner, M.P.H., and Barbara A. Morse, Ph.S., executive di-
rector and program director respectively. 
As part of the grant, three pilot sites around the city will be se-
lected for intensive training sessions on FAS. Weiner and 
Morse, in collaboration with Sean Palfrey, M.D., chief of ambula-
tory pediatrics at Boston City Hospital, have initiated training for 
pediatric house staff at BCH. In addition, an educational hand-
book geared specifically to the needs of pediatricians will be de-
veloped, and distributed to pediatricians nationally. 
The MetPath Foundation is funded by MetPath, Inc., a na-
tional clinical diagnostic laboratory. For more information about 
the grant program, call the Fetal Alcohol Education Program at 
617/739- 1424. 
Interinstitutional task force appointed on 
minority faculty recruitment, retention 
The Task Force on Minority Faculty Recruitment and Retention 
recently was convened by Dean Aram V. Chobanian, Judith 
Kuriand, commissioner of the Department of Health and Hospi-
tals, and J. Scott Abercrombie Jr., M.D., president of Boston 
University Medical Center/The University Hospital. The task 
force, which has begun to meet monthly under the direction of 
Kenneth Edelin, M.D., associate dean for student and minority 
affairs at the School, is composed of a diverse group of individu-
als from all three facilities. 
The purpose of the task force is to examine current mecha-
nisms for the recruitment of minority faculty to the Medical 
Campus and recommend changes that will enable department to 
be more successful in their recruitment efforts. The task force 
also will consider and recommend strategies to improve the re-
tention of minority faculty. Edelin anticipates that the group's 
recommendations on this important issue will be ready by early 
summer. 
Leeman receives 1993 FASEB 
Excellence in Science Award 
Susan E. Leeman, Ph.D., a professor of pharmacology, recently 
was selected as the recipient of the 1993 FASEB (Federation of 
American Societies for Experimental Biology) Excellence in Sci-
ence Award. The award is presented annually to a woman scien-
tist who has contributed significantly to further the 
understanding of a particular discipline by excellence in re-
search. According to Shu Chien, M.D., Ph.D., president of 
FASEB, Leeman has made "outstanding contributions to the 
field of neuroendocrinology" and has had "a major impact on 
scientists in a wide variety of disciplines." As the recipient of 
the award, Leeman will present the Excellence in Science Lec-
ture during the Experimental Biology '93 meeting to be held in 
New Orieans from March 28 to April 1. 
Pediatric dept. events on May 13,14 
to honor Alport's 21-year tenure 
BCH/BUSM's annual Pediatric Alumni events this year will 
honor Joel J. Alpert, M.D., chairman of the Department of Pedi-
atrics at the School of Medicine. Alpert will be retiring as chair-
man this year after 21 years of service. 
The annual Pediatric Lectureship, which will feature N. Paul 
Rosman, M.D., former director of BCH's Division of Pediatric 
Neurology and currently a professor of pediatrics and neurology 
at Tufts University School of Medicine, will be held on May 13 
at noon in the Dowling Amphitheater at BCH. The annual 
Alumni Dinner will be held later that evening. 
On May 14, a Festschrift in Alpert's honor will begin at 8 
a.m. in the Dowling Amphitheater, followed by a luncheon at 
the School of Medicine's Hiebert Lounge at noon. 
For more information on these events, contact Trysha Ahem, 
Pediatric Alumni coordinator, at 534-7408. 
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Briefly noted 
Nancy Avis, Ph.D., an adjunct assistant professor of public 
health and a nationally recognized expert on menopause, dis-
cussed the psychosocial and cultural issues surrounding meno-
pausal women during a two-day conference sponsored by Elliot 
Health System and the University of New Hampshire on Feb. 11 
and 12. Avis currently is the director of the Institute for 
Women's Research and is a principal research scientist at the 
New England Research Institute....PhyIlis J. Stevens, director of 
Minority Affairs, recently began a two-year term as chairperson 
of the Northeast Region Group on Student Affairs-Minority Af-
fairs Section of the American Association of Medical Colleges 
(AAMC). Stevens' role, both with the School of Medicine and 
the AAMC, involves increasing the number of minorities in 
medicine and fostering mutual understanding and acceptance for 
medical students of different backgrounds. 
Upcoming CME courses 
The following is a list of upcoming courses sponsored by the De-
partment of Continuing Medical Education: 
"Controversies in Internal Medicine" will be held from 
May 10 through May 14 at the Hilton Resort in Hilton Head, S.C. 
"Facial Skin Malignancies: Update on Diagnosis, Treat-
ment and Reconstruction" will take place from May 14 through 
May 15 at the Royal Sonesta Hotel in Cambridge, Mass. 
"Advances in Medicine" will be held from May 31 through 
June 4 at the Sheraton Hotel in Boston. 
For further information, contact the Department of Continuing 
Medical Education, 80 E. Concord St., Boston, MA 02118, or 
call (617) 638-4605 (x4605). 
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